PMID: 8601580Jan 1, 1996Paper

Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA

Journal of Cancer Research and Clinical Oncology
T KozuH Fujiki

Abstract

For therapeutic purposes, two chimeric DNA/RNA hammerhead ribozymes were synthesized to cleave AML1/MTG8, the t(8;21)-associated fusion mRNA of acute myeloid leukemia. One ribozyme, A/MRZ-1, recognizes the area adjacent to the fusion point between AML1 and MTG8, and cleaves six bases downstream from this point. The other, MRZ-1, recognizes the MTG8 sequence. Both ribozymes cleaved synthetic chimeric DNA/RNA substrates at theoretical sites. Neither cleaved AML1 RNA. A/MRZ-1 cleaved only AML1/MTG8 RNA, and MRZ-1 cleaved both AML1/MTG8 and MTG8 RNAs. The two ribozymes showed growth inhibition of an acute myeloid leukemia cell line carrying t(8;21), SKNO-1 cells. The same extent of growth inhibition was attained by antisense oligonucleotides against AML1/MTG8 RNA. The results suggest that the ribozyme has the potential to be developed as a useful agent for gene therapy, in particular for leukemia with t(8;21).

References

Dec 25, 1990·Biochemistry·J H YangR Cedergren
Dec 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H MiyoshiM Ohki
Jan 1, 1986·Annual Review of Biochemistry·T R Cech, B L Bass
Oct 13, 1995·Biochemical and Biophysical Research Communications·H MatsushitaY Ikeda
Jan 1, 1995·British Medical Bulletin·J J Rossi
Nov 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·K ShimizuM Ohki

❮ Previous
Next ❯

Citations

Apr 1, 1997·Molecular Biotechnology·S A Gibson, E J Shillitoe
Oct 18, 2003·Seminars in Cancer Biology·Christine Damm-WelkArndt Borkhardt
Jun 26, 2001·European Journal of Biochemistry·M SzyrachO Heidenreich
May 17, 2003·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·David SteeleGarrett A Soukup
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·E S MassudaT P Cripe
Nov 4, 2000·Expert Opinion on Investigational Drugs·H A James
Jul 19, 2001·Cancer Investigation·L Wright, P Kearney
Jan 25, 2002·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·S P Lyngstadaas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.